Prostate cancer cells express tissue-specific proteins that could act as therapeutic targets, among others PSA, PAP, PSMA and prostate cancer usually progresses at relatively slow pace, which might allow for the elicitation of an effective immune response [31]. Here, FOLH1 is linked to prostate carcinoma.